2[1]Adler M, Schaffner F. Fatty liver hepatitis and cirrhosis inobese patients[J]. Am J Med, 1979, 67:811.
3[2]Ludwig J, Viggiano T R., McGill D B, et al. Nonalcoholicsteatohepatitis Mayo Clinic experiences with a hitherto unnameddisease [ J]. Mayo Clin Proc, 1980,55: 434.
4[3]Sanyal A J. AGA technical review on nonalcoholic fatty liverdisease[J]. Gastroenterology, 2002, 123: 1 705.
5[4]Powell E E, Cooksley W G E, Hanson R, et al. The naturalhistory of nonalcoholic steatohepatitis: A follow - up study offorty- two patients for up to 21 yeaFs[J]. Hepatology, 1990,11:74.
6[5]Bacon B R, Farahvaash M J, Janney C-G, et al. Nonalcoholicsteatohepatitis: An expanded clinical entity [ J ]. Gastr-oenterology, 1994,107:1 103.
7[6]Wanless I R and Lentz J S. Fatty liver hepatitis(steatohepatitis) and obesity: An autopsy study with analysis ofrisk factors[J]. Hepatology, 1990,12:1 106.
8[7]Lindor K D, Kowdley K V, Heathcote E J, et al.Ursodeoxycholic acid for treatment of nonalcohohcsteahohepatitis: results of a randomized trial[J]. Hepatology,2004, 39: 770.
9[10]Hasegawa T, Yoneda M, Nakamura K, et al. Plasmatransforming growth factor - beta 1 level and efficacy of alpha -tocopherol in patients with non alcoholic steatohepatitis: a pilotstudy[J]. Aliment Pharmacol Ther , 2001,15:1 667.
10[11]Velussi M, Cemigoi A M, De Monte A, et al. Long term( 12months) treatment with an anti oxidant drug (silymarin) iseffective on hyperinsulinemia, exogenous insulin need, andmalondialdehyde levels in cirrhotic diabetic patient [ J]. Jhepatol,1997,26: 871.
